Kedrion S.p.a.
Clinical trials sponsored by Kedrion S.p.a., explained in plain language.
-
New hope for chronic ITP: IVIg 10% trial seeks to boost platelets
Disease control Recruiting nowThis study tests a medicine called KIg 10 (a type of IVIg) in 40 adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The goal is to see if the treatment safely raises platelet counts and reduces bleeding. Pa…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated May 26, 2026 06:00 UTC
-
New study seeks better dose of immune therapy for nerve disease
Disease control Recruiting nowThis study tests two different doses of an intravenous immune globulin (IGIV 10%) as maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. About 161 participants will receive either a higher o…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated May 26, 2026 05:43 UTC
-
New hope for rare bleeding disorder: coagadex trial targets AL amyloidosis complications
Disease control Recruiting nowThis study tests a drug called Coagadex in 15 adults with acquired factor X deficiency caused by AL amyloidosis. The goal is to see if it safely stops bleeding episodes and helps manage bleeding during surgery. Participants receive the drug and are monitored for response over 72 …
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC